Hemophilia is a rare, X-linked genetic disorder associated with significant health and economic impacts as well as quality-of-life concerns for patients. Hemophilia can be divided into two categories: A and B. Hemophilia A involves a deficiency in clotting factor VIII, and hemophilia B involves a deficiency in clotting factor IX. Novel therapies are in the pipeline that may significantly reduce the pharmacotherapy burden for patients, improve outcomes, and reduce costs. The goal of this project is to review therapeutic options for the treatment of hemophilia A and B, with an emphasis on novel pharmacotherapy. Our search strategy includes Ovid Medline and Google Scholar with the following key terms: hemophilia, factor VIII, factor IX, pharmacotherapy, gene therapy. The results of this study will be used to educate healthcare providers on the literature supporting novel agents in the pipeline for the treatment of hemophilia, including the management of toxicities associated with administration.